A Study of LOXO-260 in Cancer Patients With a Change in a Particular Gene (RET) That Has Not Responded to Treatment

Active:	No
Cancer Type:	Solid Tumor Unknown Primary	NCT ID:	NCT05241834
Trial Phases:	Phase I	Protocol IDs:	LOXO-NGR-21001 (primary) NCI-2022-01823 J3T-OX-JZTA
Eligibility:	12 Years and older, Male and Female	Study Type:	Treatment
Study Sponsor:	Eli Lilly and Company
NCI Full Details:	http://clinicaltrials.gov/show/NCT05241834

Summary

The main purpose of this study is to learn more about the safety, side effects, and
effectiveness of LOXO-260. LOXO-260 may be used to treat cancer that has a change in a
particular gene (known as the RET gene). Participation could last up to 24 months (2
years) and possibly longer if the disease does not get worse.

Treatment Sites in Georgia

Winship Cancer Institute of Emory University
1365 Clifton Road NE
Building C
Atlanta, GA 30322
winshipcancer.emory.edu

**Clinical trials are research studies that involve people. These studies test new ways to prevent, detect, diagnose, or treat diseases. People who take part in cancer clinical trials have an opportunity to contribute to scientists’ knowledge about cancer and to help in the development of improved cancer treatments. They also receive state-of-the-art care from cancer experts... Click here to learn more about clinical trials.